smmu008
Lv5
1600 积分
2022-01-17 加入
-
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
11天前
已完结
-
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
11天前
已完结
-
Practical Guide to Statistical Considerations in Clinical Trials in Surgery
19天前
已完结
-
2022年中国恶性肿瘤流行情况分析
1个月前
已完结
-
Cancer incidence and mortality in China, 2022
1个月前
已完结
-
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial
1个月前
已完结
-
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport]
2个月前
已完结
-
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials
2个月前
已完结
-
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
3个月前
已完结
-
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
4个月前
已完结